Keytruda works by inhibiting the activity of the programmed cell death protein 1 (PD-1), which typically limits the activity of your immune system. Cancer cells often produce PD-1 to prevent your ...

The FDA approved Keytruda for NSCLC based on several clinical trials. Keytruda was studied in people whose NSCLC had spread to other parts of the body (metastatic) and who had received no prior ...

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.

As Keytruda’s 2028 patent cliff looms large, Merck & Co.’s renewed R&D oncology strategy focuses on three strategies. One of those prongs is improving immune responses, a pillar that stars ...

Keytruda is not chemotherapy. It’s a type of treatment called immunotherapy. It works with the body’s immune system, helping T cells fight cancer cells. With immunotherapy, the body’s immune system ...

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific ...

Represents the first PD-1 inhibitor plus ADC regimens for this patient population These approvals are based on data from the Phase 3 KEYNOTE-905 trial (also known as EV-303), which was conducted in ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...

Keytruda and Padcev combination improved survival in muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy. The KEYNOTE-905 trial showed significant event-free survival ...